Skip to main content
News Icon

COVIMMUNE being funded

A new consortium COVIMMUNE under the direction of Prof. Eicke Latz, speaker of the cluster of Excellence ImmunoSensation2 is being funded with around 2 Million Euros by the Federal Ministry of Education and Research (BMBF). The project "Understanding divergent host reactions to SARS-CoV-2 infections by precision immunology" (COVIMMUNE) brings together clinical researchers at the University Hospital Bonn who are involved in COVID-19 patient care with basic scientists with immunological expertise from the University of Bonn.

"We want to find out the connection between the mechanisms of the immune response to the SARS-CoV-2 infection and the clinical course of the disease," says Prof. Dr. Eicke Latz. Around two dozen personalities from disciplines such as virology, internal medicine, intensive care medicine, pulmonology, neurology, immunology, blood coagulation, bioinformatics and systems biology are involved. Together they want to contribute to a better understanding of the different course of the disease in SARS-CoV-2 infections. Prof. Natalio Garbi heads the sub-project of the consortium on adaptive immunity. He says: "We want to test whether the interaction of the innate and the acquired (adaptive) immune response is the key to eliminating the infection and developing long-term immunity without long-term health consequences."

The aim is to find out how the SARS-CoV-2 virus can trigger a misdirected immune response and what role this plays in severe COVID-19 disease courses. Furthermore, a clinical study will investigate which factors cause long-term damage to the lungs and the nervous system. Prof. Dr. Michael Heneka, whose sub-project in the consortium is looking at the secondary diseases of the lungs and the central nervous system caused by COVID-19, says: "It is not yet well understood how infection with the SARS-CoV-2 virus can trigger such secondary diseases. We want to examine these relationships in a clinical study in order to be able to offer better treatment options."


Contact

Prof. Dr. Eicke Latz

Institute of Innate Immunity, University of Bonn

Phone: 0228/287-51223

E-Mail: eicke.latz@uni-bonn.de

Related news

Dermatologist Prof. Jörg Wenzel – from Bonn University Hospital (UKB) and the University of Bonn – leads the Bonn subproject within the new DFG-funded research consortium FOR 6059, which investigates the mechanisms underlying cutaneous lupus. © Bonn University Hospital (UKB) / Alessandro Winkler

Honors & Funding

New Research Group Investigates Cutaneous Lupus

—The German Research Foundation (DFG) is funding a new research group dedicated to investigating cutaneous lupus erythematosus, an autoimmune disease affecting the skin. A team from Bonn University Hospital (UKB) and the University of Bonn is participating in the collaborative research project “Investigating the Immunopathogenesis of Cutaneous Lupus Erythematosus” (FOR 6059), which is led by the Department of Dermatology at the University Hospital Tübingen.
View entry
Neurons - generated through the differentiation of induced neural stem cells (iNSCs) derived from blood.

Publication

Researchers Transform Old Blood Cells into Young Brain Cells

—Researchers from the University Hospital of Bonn and the University of Bonn have succeeded in dramatically rejuvenating human cells in a test tube. To do so, they directly reprogrammed red blood cell precursors into stem cells from which neurons can be derived. During this process, the molecular clocks that indicate a cell’s age were reset. For example, blood cells from an 80-year-old were transformed into stem cells with a molecular age of less than 20 years. The results have been published in the journal Aging Cell.
View entry
Dr. Robert Hüneburg, Dr. Anne-Sophie Layritz, and Nicola Reents (from left) - conducted a survey and found that fewer than one in ten people with Lynch syndrome take Acetylsalicylic acid for cancer prevention – despite a high level of openness to new preventive approaches.

Publication

Aspirin Rarely Used for Colorectal Cancer Prevention

—According to international studies, taking Acetylsalicylic acid daily can protect people with Lynch syndrome from developing colorectal cancer – even at low doses. Researchers from the University Hospital Bonn (UKB), the University of Bonn, and the Center for Integrated Oncology (CIO) Bonn, in collaboration with the self-help organization SemiColon, have now found that these scientific findings have so far been insufficiently incorporated into clinical practice. The results of the LYNX study have now been published as a letter in the journal The Lancet Gastroenterology & Hepatology.
View entry

Back to the news overview